Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

Nippon Kayaku increases dividend for 2026 by 10% to 66.00 JPY

At its shareholders' meeting, Nippon Kayaku approved a dividend of 66.00 JPY per share for 2026, up 10% from the previous year. A total of 10.56 billion JPY will be distributed, with a dividend yield of 3.76% (previous year 4.25%). The share price rose 58.88% over the year, and the total return including the dividend was 59.17%. FactSet estimates assume an unchanged payout, which would lower the yield to 3.25%. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2026, NIPPON KAYAKU has already paid €0.20 in dividends. The last payout was in June.

Financials

In the last quarter, NIPPON KAYAKU had revenue of €363.12m and net profit of €32.77m

(EUR)	June 2026	YoY
Revenue	363.12m	12.40%
Gross profit	112.67m	15.28%
Net profit	32.77m	29.40%
EBITDA	36.31m	36.93%

Fundamentals

Metric	Value
Market capitalization	€1.71bn
Number of shares	147.25m
52-week high/low	€12.47 - €7.83
Dividend yield	3.12%
Dividends TTM	€0.36
Beta	0.77
P/E ratio	11.64
PEG ratio	0.21
P/B ratio	1.07
P/S ratio	1.18

Company profile

Nippon Kayaku Co., Ltd., together with its subsidiaries, develops, manufactures, and sells functional chemicals, pharmaceuticals, safety systems, and agrochemicals and other products in Japan and internationally. The company's Functional Chemicals Business segment offers functional materials, such as epoxy resins, UV-curable resins, sealants for LCD and LED, touch panel adhesives, and microelectromechanical systems. This segment also provides color materials, including inkjet colorants, dyes for textiles and papers, and materials for thermal paper; catalysts for the production of acrylic and methacrylic acid; and polarizing films, inorganic polarizing plates, LCD projector parts, x-ray analytical equipment, and application products. Its Pharmaceuticals Business segment offers anti-cancer and cancer-related drugs, biosimilars, generic drugs, interventional radiology products, cardiovascular drugs, bulk drugs and intermediates of pharmaceuticals, and drugs for diagnosing cancer, as well as GlycoMark, a product as a marker of blood sugar control used for diabetes. The company's Safety Systems Business segment provides airbag inflators, micro gas generators for seatbelt pretensioners, and squibs. Its Other segment offers agricultural insecticides, herbicides, soil fumigants, and insanitary insecticides; and real estate leasing services. The company was formerly known as Nihon Kayaku Seizou Co., Ltd. and changed its name to Nippon Kayaku Co., Ltd. in 1945. Nippon Kayaku Co., Ltd. was incorporated in 1916 and is headquartered in Tokyo, Japan.